February 27, 2018 / 9:57 PM / 4 months ago

BRIEF-Acceleron Pharma Q4 Loss Per Share $‍0.62​

Feb 27 (Reuters) - Acceleron Pharma Inc:

* ACCELERON REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING AND FINANCIAL RESULTS

* ‍TOP-LINE RESULTS FROM MEDALIST AND BELIEVE PHASE 3 TRIALS OF LUSPATERCEPT ARE EXPECTED IN MID-2018​

* ‍ON TRACK TO INITIATE A PHASE 2 TRIAL IN PULMONARY ARTERIAL HYPERTENSION IN 1H 2018​

* QTRLY LOSS PER SHARE $‍0.62​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below